Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...
A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback